Adaptive and Flexible Clinical Trials

Author:   Richard Chin
Publisher:   Taylor & Francis Inc
ISBN:  

9781439838327


Pages:   198
Publication Date:   25 August 2011
Format:   Hardback
Availability:   In Print   Availability explained
This item will be ordered in for you from one of our suppliers. Upon receipt, we will promptly dispatch it out to you. For in store availability, please contact us.

Our Price $204.00 Quantity:  
Add to Cart

Share |

Adaptive and Flexible Clinical Trials


Add your own review!

Overview

Full Product Details

Author:   Richard Chin
Publisher:   Taylor & Francis Inc
Imprint:   CRC Press Inc
Weight:   0.498kg
ISBN:  

9781439838327


ISBN 10:   1439838321
Pages:   198
Publication Date:   25 August 2011
Audience:   Professional and scholarly ,  Professional & Vocational
Format:   Hardback
Publisher's Status:   Active
Availability:   In Print   Availability explained
This item will be ordered in for you from one of our suppliers. Upon receipt, we will promptly dispatch it out to you. For in store availability, please contact us.

Table of Contents

Reviews

... later chapters in the book ... are most useful. They describe the various types of adaptations that can be used. ... This book is helpful for a starter in adaptive designs, to get an idea of the visions behind applying such designs. -Philip Hougaard and Corine Baayen, ISCB Newsletter, June 2013


Author Information

Richard Chin, M.D. is the Chief Executive Officer of OneWorld Health, a nonprofit pharmaceutical company largely funded by the Bill and Melinda Gates Foundation, developing drugs for impoverished patients in the developing world.a Previously, Dr. Chin held multiple senior positions in several biotechnology companies and has extensive expertise in drug development including 10 new drug registrations filings/launches and over 45 Investigational New Drug (IND) Applications. Some of the drugs he has overseen include Rituxan, Lucentis, Tysabri, TNKase, Raptiva, Xolair, Cathflo, Prialt, Protropin, Nutropin, Pulmo- zyme, Azactam, Maxipime, and Bapineuzumab, among others. Dr. Chin was named by Businessweek in 2006 as one of the youngest 99 public company CEOs in the United States. Dr. Chin earned his M.D. from Harvard and the equivalent of a J.D. from Oxford, where he studied as a Rhodes Scholar. Dr. Chin serves as Associate Professor at UCSF School of Medicine and was previously on the adjunct faculty at Stanford University School of Medicine.

Tab Content 6

Author Website:  

Customer Reviews

Recent Reviews

No review item found!

Add your own review!

Countries Available

All regions
Latest Reading Guide

MRG2025CC

 

Shopping Cart
Your cart is empty
Shopping cart
Mailing List